vs
Side-by-side financial comparison of ACHIEVE LIFE SCIENCES, INC. (ACHV) and MYRIAD GENETICS INC (MYGN). Click either name above to swap in a different company.
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the Nasdaq-100 and the S&P 100.
Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life, identify a pati...
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $209.8M | ||
| Q3 25 | — | $205.7M | ||
| Q2 25 | — | $213.1M | ||
| Q1 25 | — | $195.9M | ||
| Q4 24 | — | $210.6M | ||
| Q3 24 | — | $213.3M | ||
| Q2 24 | — | $211.5M | ||
| Q1 24 | — | $202.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | $-27.4M | ||
| Q2 25 | — | $-330.5M | ||
| Q1 25 | — | $-100.0K | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-22.1M | ||
| Q2 24 | — | $-36.7M | ||
| Q1 24 | — | $-26.0M |
| Q4 25 | — | 70.0% | ||
| Q3 25 | — | 69.9% | ||
| Q2 25 | — | 71.2% | ||
| Q1 25 | — | 68.5% | ||
| Q4 24 | — | 71.7% | ||
| Q3 24 | — | 70.2% | ||
| Q2 24 | — | 69.6% | ||
| Q1 24 | — | 68.1% |
| Q4 25 | — | -2.7% | ||
| Q3 25 | — | -11.3% | ||
| Q2 25 | — | -154.5% | ||
| Q1 25 | — | -14.8% | ||
| Q4 24 | — | -18.6% | ||
| Q3 24 | — | -9.4% | ||
| Q2 24 | — | -17.3% | ||
| Q1 24 | — | -13.8% |
| Q4 25 | — | — | ||
| Q3 25 | — | -13.3% | ||
| Q2 25 | — | -155.1% | ||
| Q1 25 | — | -0.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -10.4% | ||
| Q2 24 | — | -17.4% | ||
| Q1 24 | — | -12.9% |
| Q4 25 | — | $-0.09 | ||
| Q3 25 | — | $-0.29 | ||
| Q2 25 | — | $-3.57 | ||
| Q1 25 | — | $0.00 | ||
| Q4 24 | — | $-0.47 | ||
| Q3 24 | — | $-0.24 | ||
| Q2 24 | — | $-0.41 | ||
| Q1 24 | — | $-0.29 |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
